Dana Rizk
Program Director · University of Alabama Hospital
Credentials: · · · ·
History
- Present
Heersink School of Medicine · University of Alabama Hospital
- 2000–2002
Nephrology
- 1997–2000
Internal Medicine
Research
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy
New England Journal of Medicine · 2019 · 496 citations
IgA Nephropathy: An Interesting Autoimmune Kidney Disease
Review · The American Journal of the Medical Sciences · 2021 · Last of 3 authors · Corresponding · 188 citations
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
New England Journal of Medicine · 2025 · 161 citations
19 papers
15 papers · 14 as a resident
13 papers
- AR
11 papers
- DW
10 papers
8 papers
- LM
8 papers
- WM
7 papers
Clinical trials
- 2013–2014
FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.
Principal investigator · Completed
FAST BioMedical
- 2025–2030
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Site PI · Recruiting · Phase 3
Takeda
- 2025–2027
Site PI · Recruiting · Phase 2
Novartis Pharmaceuticals
- 2020–2030
Belimumab With Rituximab for Primary Membranous Nephropathy
Site PI · Recruiting · Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)